All Articles

Roles and potential applications of non-coding RNAs in cancer treatment with immune checkpoint inhibitors and immunomodulatory therapies

Immunotherapy resistance and strategies in malignant pleural mesothelioma

Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapies

Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies

Interactions between tumor microenvironment and resistance to transarterial and systemic treatments for HCC

Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma

Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment

The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer

Overcoming immuno-resistance by rescheduling anti-VEGF/cytotoxics/anti-PD-1 combination in lung cancer model

Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma

Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies

Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia

Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena

Mechanisms and clinical implications in renal carcinoma resistance: narrative review of immune checkpoint inhibitors

Immune checkpoint inhibitors in ovarian cancer: where do we go from here?

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer

Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer